



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

BENNEKER et al.

Appl. No.: 09/200,743

Filed: November 30, 1998

For: CRYSTALLINE PAROXETINE  
METHANE SULFONATE

Art Unit: 1625

Examiner: Chang, C.

Atty Docket POT-010US2

TECH CENTER 1600/2900

MAR 21 2002

RECEIVED

**Information Disclosure Statement  
Pursuant To 37 C.F.R. § 1.97(c)**

Assistant Commissioner for Patents  
Washington, DC 20231

March 20, 2002

Sir:

Applicants hereby direct the attention of the U.S. Patent and Trademark Office to the document listed on the attached Form PTO/SB/08A. Applicants respectfully request that this document be expressly considered during the prosecution of this application, be made of record therein, and appear among the "References Cited" on any patent to issue therefrom. A copy of the listed document is attached.

As the Examiner is aware, the submission of this statement is not to be construed as an admission that any document is prior art to the present invention or that any document is material to patentability as defined in rule 56.


This Information Disclosure Statement is being filed pursuant to 37 C.F.R. § 1.97(c), after a first Office Action on the merits, but before a final rejection or Notice of allowance. Therefore, the Information Disclosure Statement filing fee under 37 C.F.R. §

1.17(p) applies. Please charge the required filing fee in the amount of \$180.00 to Deposit Account No. 502109.

Please charge any deficiency in fees or credit any overpayment to Deposit Account No. 502109.

Should the Examiner have any questions regarding this application, she is encouraged to contact applicants' undersigned representative at telephone No. 703 753 8791.

Respectfully submitted,



Mark R. Buscher  
Registration No. 35,006  
Phone: (703) 753-8791  
Fax: (703) 753-8891

Synthon Pharmaceuticals, Ltd.  
P.O. Box 161  
Catharpin, VA 20143